Evidence map›Paper›PMID 38348418›Full record

ArticleFrontiers in endocrinology2024

A family case report of parathyroid carcinoma associated with

Yian Gu, Yuanyuan Ye, Hua Shu, Lina Chang, Yinghui Xie, Fengao Li, Tiehong Zhu, Ming Liu, Qing He

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yian Gu *Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Yuanyuan Ye *Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Hua ShuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Lina ChangDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Yinghui XieDepartment of Endocrinology and Metabolism, Baodi District People's Hospital, Tianjin, China.
Fengao LiDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Tiehong ZhuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Ming LiuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Qing HeDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Tianjin Medical University General Hospital · CNTianjin People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary primary hyperparathyroidism (PHPT) accounts for 5-10% of all PHPT cases, necessitating genetic testing for diagnosis and management. Among these, hyperparathyroidism-jaw tumor syndrome (HPT-JT) is an autosomal dominant disorder caused by Case summary: The proband, diagnosed with PHPT, underwent parathyroidectomy at the age of 41 with pathological examination of parathyroid carcinoma (PC). Hereditary PHPT was initially suspected due to the early-onset PHPT and family history. Genetic testing identified a heterozygous Conclusion: Genetic testing is strongly recommended in cases of early-onset PHPT, family history, jaw tumors, renal and uterine involvement, atypical parathyroid tumors, and PC. This testing provides valuable information for personalized management, and counseling is available for affected families.

Indexed as

AdenomaFibromaHyperparathyroidismJaw NeoplasmsParathyroid NeoplasmsAdultHumansMutationTumor Suppressor ProteinsCDC73 protein, humanTumor Suppressor ProteinsCDC73 genehereditary primary hyperparathyroidismhyperparathyroidism-jaw tumor syndromeparafibrominparathyroid carcinoma

Identifiers

PMID38348418
PMCPMC10859429
OpenAlexW4391320799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.